Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: A randomized clinical trial

CMAJ

Volumn 189, Issue 24, 2017, Pages E819-E827

  ElSherif, May S ^a   Brown, Catherine ^a   Mackinnon Cameron, Donna ^a   Li, Li ^a   Racine, Trina ^b   Alimonti, Judie ^b   Rudge, Thomas L ^c   Sabourin, Carol ^c   Silvera, Peter ^d   Hooper, Jay W ^d   Kwilas, Steven A ^d   Kilgore, Nicole ^e   Badorrek, Christopher ^e   Jay Ramsey, W ^f   Gray Heppner, D ^f   Kemp, Tracy ^f   Monath, Thomas P ^f   Nowak, Teresa ^g   McNeil, Shelly A ^a   Langley, Joanne M ^a   Halperin, Scott A ^a   more..

^a DALHOUSIE UNIVERSITY   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^e Joint Vaccine Acquisition Program   (United States)

^f NEWLINK GENETICS   (United States)

^g Veristat   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; IMMUNOGLOBULIN G; LIVE VACCINE; PLACEBO; RECOMBINANT VACCINE; RECOMBINANT VESICULAR STOMATITIS VIRUS EBOLA VACCINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; G PROTEIN, VESICULAR STOMATITIS VIRUS; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EBOLA HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MYALGIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; URINALYSIS; VACCINE IMMUNOGENICITY; VESICULOVIRUS; VIREMIA; VIRUS RECOMBINANT; VIRUS SHEDDING; ADOLESCENT; ANIMAL; BLOOD; CANADA; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; EBOLAVIRUS; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MIDDLE AGED; NORMAL HUMAN; PROCEDURES; REGRESSION ANALYSIS; VACCINATION; VESICULAR STOMATITIS INDIANA VIRUS; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CANADA; DOUBLE-BLIND METHOD; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HEALTHY VOLUNTEERS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; REGRESSION ANALYSIS; VACCINATION; VACCINES, SYNTHETIC; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; YOUNG ADULT;

EID: 85021071438     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.170074     Document Type: Article

References (32)

1. Urbanowicz RA, McClure CP, Sakuntabhai A, et al. Human adaptation of Ebola virus during the West African outbreak. Cell 2016;167:1079-87. e5.
2. Ebola virus disease [situation report]. Geneva: World Health Organization; 2016. Available: http://apps.who.int/iris/bitstream/10665/208883/1/ebolasitrep -10Jun2016-eng.pdf?ua=1 (accessed 2017 Jan. 20).
3. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004;78:5458-65.
4. Schnell MJ, Buonocore L, Kretzschmar E, et al. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated eficiently into virus particles. Proc Natl Acad Sci U S A 1996;93:11359-65.
5. Letchworth GJ, Rodriguez LL. Del cbarrera J. Vesicular stomatitis. Vet J 1999;157:239-60.
6. Lichty BD, Power AT, Stojdl DF, et al. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004;10:210-6.
7. Takada A, Feldmann H, Stroeher U, et al. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 2003;77:1069-74.
8. Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 2012;6:e1567.
9. Watanabe S, Takada A, Watanabe T, et al. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol 2000;74:10194-201.
10. Feldmann H, Jones SM, Daddario-Di Caprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007;3:e2.
11. Daddario-Di Caprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006;367:1399-404.
12. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virusbased ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008;4:e1000225.
13. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virusbased vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008;26:6894-900.
14. Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11:786-90.
15. Guideline for good clinical practice E6 (R2): step 5. London (UK): European Medicines Agency; 2016. Available: www.ema.europa.eu/docs/en-GB/document - library/Scientific-guideline/2009/09/WC500002874.pdf (accessed 2017 Mar. 9).
16. Regules JA, Beigel JH, Paolino KM, et al. rVSV-G-ZEBOV-GP Study Group. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 2017;376:330-41.
17. Rudge TL Jr, Badorrek C, Rodriguez N, et al. Qualification and validation of filovirus anti-glycoprotein immunoglobulin ELISAs. Abstract at Chemical and Biological Defense Program 2015, DTRA: rVSV Ebola Vaccine Science Review; July 2015; Arlington, Va.
18. Rudge TL Jr, Sankovich K, Kurnat K, et al. Development and qualification of a human filovirus anti-glycoprotein immunoglobulin ELISAs. Abstract at the 7th International Symposium on Filoviruses; March 2015; Washington, DC.
19. Sabourin CL, Rudge TL Jr, Gainey M, et al. Development and qualification of filovirus anti-glycoprotein immunoglobulin ELISAs. Abstract at the 6th International Symposium on Filoviruses; March-April 2014; Galveston, Tex.
20. Ray N, Whidby J, Stewart S, et al. Study of Andes virus entry and neutralization using a pseudovirion system. J Virol Methods 2010;163:416-23.
21. Ogino M, Ebihara H, Lee BH, et al. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin Diagn Lab Immunol 2003;10:154-60.
22. Grant-Klein RJ, Van Deusen NM, Badger CV, et al. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vaccin Immunother 2012;8:1703-6.
23. Kwilas S, Kishimori JM, Josleyn M, et al. A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. Curr Gene Ther 2014;14:200-10.
24. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016;374:1647-60.
25. Kanapathipillai R, Henao Restrepo AM, Fast P, et al. Ebola vaccine - an urgent international priority. N Engl J Med 2014;371:2249-51.
26. Huttner A, Dayer JA, Yerly S, et al. VSV-Ebola Consortium. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised doubleblind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015;15:1156-66.
27. Pavot V. Leading Ebola vaccine candidates. Vaccin Res Open J 2016;1:1-6.
28. GlaxoSmithKline. Safety and immunogenicity study of GSK biologicals' investigational recombinant chimpanzee adenovirus type 3-vectored Ebola Zaire vaccine (GSK3390107A) in children in Africa. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. Available: https://clinicaltrials.gov/ct2/show/NCT02548078 (accessed 2016 Nov. 3). NLM identifier: NCT02548078.
29. GlaxoSmithKline. Safety and immunogenicity study of GSK biologicals' investigational recombinant chimpanzee adenovirus type 3-vectored Ebola Zaire vaccine (GSK3390107A) in adults in Africa. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. Available: https://clinicaltrials.gov/ct2/show/NCT02485301 (accessed 2016 Nov. 3). NLM identifier: NCT02485301.
30. National Institute of Allergy and Infectious Diseases. Partnership for Research on Ebola Vaccines in Liberia (PREVAIL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. Available: https://clinicaltrials.gov/ct2/show/NCT02344407 (accessed 2016 Nov. 3). NLM identifier: NCT02344407.
31. Shiwani HA, Pharithi RB, Khan B, et al. An update on the 2014 Ebola outbreak in Western Africa. Asian Pac J Trop Med 2017;10:6-10.
32. Statement on the 9th meeting of the IHR Emergency Committee regarding the Ebola outbreak in West Africa [statement]. Geneva: World Health Organization; 2016. Available: www.who.int/mediacentre/news/statements/2016/end-of ebola-pheic/en/ (accessed 2017 Mar. 10).